Pharmaceutical Formulations

Formulation studies involve developing a preparation of the drug which is both stable and acceptable to the patient. For orally administered drugs, this usually involves incorporating the drug into a tablet or a capsule. It is important to make the distinction that a tablet contains a variety of other potentially inert substances apart from the drug itself, and studies have to be carried out to ensure that the encapsulated drug is compatible with these other substances in a way that does not cause harm, whether direct or indirect. Formulation studies also consider such factors as particle size, polymorphism, pH, and solubility, as all of these can influence bioavailability and hence the activity of a drug. The drug must be combined with inactive ingredients by a method which ensures that the quantity of drug present is consistent in each dosage unit e.g. each tablet. The dosage should have a uniform appearance, with an acceptable taste, tablet hardness, or capsule disintegration. By the time phase III clinical trials are reached, the formulation of the drug should have been developed to be close to the preparation that will ultimately be used in the market.

 

  • Container closure
  • Enteral formulations
  • Tablet
  • Sustained release
  • Parenteral formulations

Related Conference of Pharmaceutical Formulations

April 11-12, 2024

41th Global Nanotechnology Congress

Amsterdam, Netherlands
April 25-26, 2024

36th Nano Congress for Future Advancements

London, UK
May 16-17, 2024

27th World Nanotechnology Congress

Rome, Italy

Pharmaceutical Formulations Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in